Analytical Data
-
Gene name
PF4V1
- Application
-
Alternative Names
CXCL4L1; PF4var1; CXCL4V1; SCYB4V1; SCYB4-V1; CXCL4-V1; Chemokine(C-X-C-Motif)Ligand 4 Variant
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10720
-
Expression Region
Met1~Ser104
-
Molecular Weight
41.55kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PF4V1, or Platelet Factor 4 Variant 1, is a protein that has garnered attention in recent years due to its significant role in various physiological and pathological processes. This protein is a member of the CXC chemokine family and plays a critical role in inflammation, angiogenesis, and immune responses. Studies have shown that PF4V1 is involved in the modulation of platelet activation and aggregation, which are vital processes in hemostasis and thrombosis. Research indicates that alterations in PF4V1 expression or function may be linked to cardiovascular diseases, suggesting its potential as a biomarker for these conditions. Moreover, PF4V1's involvement in tumor microenvironments has raised interest in its potential role in cancer progression and metastasis. Recent advancements in recombinant protein technology have enabled the production of PF4V1 for further investigation into its structural and functional characteristics. Researchers are particularly focused on understanding how PF4V1 interacts with its receptors and the downstream signaling pathways it influences. By elucidating these mechanisms, the scientific community hopes to identify therapeutic targets for various diseases, including inflammatory disorders and malignancies. Overall, the study of PF4V1 as a recombinant protein holds promise for both basic science and clinical applications, paving the way for novel interventions in diseases where this protein plays a pivotal role.
